Kailera priced its initial public offering at $625 million Thursday, marking the largest life sciences market debut in 2025 and the biggest obesity-focused biotech raise on record. The company sold shares at the top of its marketed range, with CEO noting the company "knew we were in a good spot" before pricing—a rare display of confidence in a biotech IPO market that has seen fifteen withdrawn offerings since October.
The clinical-stage company is developing next-generation GLP-1 receptor agonists, entering a space dominated by Novo Nordisk's Wegovy ($21.1B in 2024 sales) and Eli Lilly's Zepbound. Kailera's lead candidate remains in Phase 2 trials, with no commercial revenue and an estimated eighteen-month runway to Phase 3 data. The company burned $147 million in cash during its last fiscal year. The IPO's success signals that institutional allocators believe the obesity market—projected to reach $130 billion by 2030—can accommodate multiple winners despite two incumbents already controlling 89% of U.S. prescriptions.
This matters because Kailera's pricing comes three weeks after Viking Therapeutics postponed its own obesity biotech IPO, citing "market conditions." The divergence suggests allocators are now separating clinical plausibility from category momentum. Kailera's differentiation centers on oral bioavailability and a once-daily dosing regimen, compared to weekly injections for current standards. The company disclosed in its S-1 that four top-twenty institutional biotech funds participated in the IPO, including names that sat out Viking's roadshow. One allocator familiar with the raise noted Kailera's management team includes former Amgen executives who successfully scaled the obesity portfolio before the 2019 spinout that became Kiniksa Pharmaceuticals.
Allocators should watch for three near-term inflection points. First, Kailera's Phase 2b trial data is expected in Q3 2025, covering 440 patients across twelve-week and twenty-four-week cohorts. Second, the company plans to initiate a cardiovascular outcomes study by year-end, a requirement that delayed Eli Lilly's Zepbound approval by fourteen months. Third, early insider lockup expirations begin in 90 days for 12% of pre-IPO shareholders, a smaller percentage than typical life sciences debuts but still worth monitoring for secondary supply.
The IPO allocated 38% of shares to long-only institutional investors, with the remainder split between crossover healthcare funds and a small retail tranche. Trading begins Friday under ticker KLRA.